The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers.
Frans Opdam
No relevant relationships to disclose
Vincent O. Dezentje
No relevant relationships to disclose
Jan den Hartigh
No relevant relationships to disclose
Henk-jan Guchelaar
No relevant relationships to disclose
Trees Hessing
No relevant relationships to disclose
Tahar van der Straaten
No relevant relationships to disclose
Robert Vree
No relevant relationships to disclose
Erdogan Batman
No relevant relationships to disclose
Eduard Maartense
No relevant relationships to disclose
Carolien H. Smorenburg
No relevant relationships to disclose
Anneke Zeillemaker
No relevant relationships to disclose
J. A. C. Brakenhoff
No relevant relationships to disclose
Maartje Los
No relevant relationships to disclose
Philomeen Kuijer
No relevant relationships to disclose
Hein Putter
No relevant relationships to disclose
Anne-Sophie Dieudonné
No relevant relationships to disclose
Patrick Neven
No relevant relationships to disclose
Cornelis J. H. Van De Velde
No relevant relationships to disclose
J. W. R. Nortier
No relevant relationships to disclose
Hans Gelderblom
No relevant relationships to disclose